BERZOSERTIB
Berzosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase ATR. In addition, it is known to target serine/threonine-protein kinase mTOR, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, and serine-protein kinase ATM.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 11 | 5 | — | — | — | 12 |
| Carcinoma | D002277 | — | C80.0 | 6 | 5 | — | — | — | 10 |
| Small cell lung carcinoma | D055752 | — | — | 4 | 4 | — | — | — | 6 |
| Small cell carcinoma | D018288 | — | — | 4 | 3 | — | — | — | 5 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 2 | — | — | — | 4 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 2 | — | — | — | 4 |
| Neuroendocrine carcinoma | D018278 | — | — | 3 | 4 | — | — | — | 4 |
| Squamous cell carcinoma | D002294 | — | — | 3 | 1 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 2 | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 1 | — | — | — | 2 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian epithelial carcinoma | D000077216 | — | — | 2 | — | — | — | — | 2 |
| Squamous cell neoplasms | D018307 | — | — | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Endometrioid carcinoma | D018269 | — | — | 1 | — | — | — | — | 1 |
| Serous cystadenocarcinoma | D018284 | — | — | 1 | — | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BERZOSERTIB |
| INN | berzosertib |
| Description | 3-[3-[4-(methylaminomethyl)phenyl]-5-isoxazolyl]-5-(4-propan-2-ylsulfonylphenyl)-2-pyrazinamine is a sulfonamide. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 1232416-25-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989870 |
| ChEBI ID | — |
| PubChem CID | 59472121 |
| DrugBank | DB11794 |
| UNII ID | L423PRV3V3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ATM
ATM
Organism
Homo sapiens
Gene name
ATM
Gene synonyms
NCBI Gene ID
Protein name
serine-protein kinase ATM
Protein synonyms
A-T mutated, AT mutated, Ataxia telangiectasia mutated, serine/threonine kinase ATM, TEL1, telomere maintenance 1, homolog
Uniprot ID
Mouse ortholog
Atm (11920)
serine-protein kinase ATM (Q62388)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 821 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use